Company: PMVP
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001140361-25-015610
Chunk: 16

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 16
---
 technology in the areas of oncology and inflammation. Dr. Mack has co-authored more than 30 scientific articles and reviews, including papers published in Cell, Science, and Nature, and is an inventor on 26 issued U.S. patents. Dr. Mack was an American Cancer Society Postdoctoral Fellow in microbiology and immunology at Stanford University School of Medicine. Dr. Mack received a B.A. in Molecular Biology from the University of California, Berkeley and a Ph.D. in Molecular Genetics and Cell Biology from the University of Chicago. We believe that Dr. Mack is qualified to serve on our board of directors because of the perspective and experience he provides as our Chief Executive Officer as well as his broad experience in the biotechnology and life sciences industries. Richard Heyman, Ph.D. has served as a member of our board of directors and as our Chairperson since June 2020. Dr. Heyman is the co-founder of ORIC Pharmaceuticals (Nasdaq: ORIC), a clinical-stage biopharmaceutical company (“ORIC”). Dr. Heyman has served on ORIC’s board of directors since March 2015 and was appointed to the chairman role in May 2018. From March 2021 through February 2023, Dr. Heyman served as chairman of Enliven Therapeutics, Inc. (Nasdaq: ELVN), a pharmaceutical company (“Enliven”), until its merger with Imara Inc., and since February 2023, has served as a member of Enliven’s board of directors. Dr. Heyman also serves as a member of the board of Vividion Therapeutics, a biopharmaceutical company, which was acquired in August 2021 by Bayer AG. Dr. Heyman served as Chairman of the board of directors of RayzeBio, Inc., a biopharmaceutical company, which was acquired in February 2024 by Bristol and Amunix Pharmaceuticals, an immuno-oncology company, which was acquired by Sanofi S.A. in December 2021. Previously, Dr. Heyman was the co-founder and Chief Executive Officer of Aragon Pharmaceuticals, a biotechnology company which was acquired by Johnson & Johnson (NYSE: JNJ), a multinational pharmaceutical, biotechnology and medical device company, in August 2013, and Seragon Pharmaceuticals, a pharmaceuticals company which was acquired by Roche Genentech in August 2014. Dr. Heyman has been involved in the discovery and development of multiple therapeutic agents approved by